Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
NTLA

Intellia Therapeutics (NTLA) stock: insider trades, news & valuation

Net buying
Close · Oct 9, 2026 $13.07 +3.7% on the day -48.7% over 12 months 52-week range $8.04 – $27.98

Share price and insider trades

NTLA closeInsider buyInsider sale
0102030NovDecJan 2026FebMarAprMayJunJulAugSepOctSold $23,170 on 2026-10-02 · Michael P DubeSold $25,052 on 2026-03-02 · Eliana Clark, James BastaSold $36,205 on 2026-08-21 · John M LeonardSold $44,316 on 2026-07-01 · Michael P DubeSold $84,186 on 2026-07-02 · Edward J Dulac IIISold $91,249 on 2026-07-22 · Edward J Dulac IIISold $250,614 on 2026-08-20 · John M LeonardSold $772,139 on 2026-01-05 · Birgit C Schultes, David Lebwohl, Edward J Dulac III, Eliana Clark, James Basta, John M Leonard, Michael P DubeSold $836,384 on 2025-12-11 · John M LeonardBought $1,402,500 on 2026-01-05 · Fred E Cohen
Bought, 12 months$1.4M
Sold, 12 months$2.2M
Insiders buying1
Insiders selling7

Intellia Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $1.4M and 7 sold $2.2M of NTLA stock on the open market.

NTLA insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $869K sold (5 trades)Q4 2025Q1 2026: $1.4M bought (1 trades)$1.4MQ1 2026: $797K sold (9 trades)Q1 2026Q2 2026Q3 2026: $507K sold (5 trades)Q3 2026Q4 2026: $23K sold (1 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$23K1
Q3 2026—0$507K5
Q2 2026—0—0
Q1 2026$1.4M1$797K9
Q4 2025—0$869K5

Valuation, profit and volume

P/E (trailing)n/aSector median —
Market value— 
Profit margin—Revenue growth —
Volume vs. 50-day2.3×Last 5 sessions
Insiders' paper profit+$558KOn all tracked purchases +39.8%

Summary

Over the past 12 months, 1 Intellia Therapeutics, Inc. insider reported open-market purchases totaling $1.4M, while 7 insiders reported sales totaling $2.2M. 6 of 20 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Oct 6SEC Michael P DubeVp, Chief Accounting Officer Sell 1,86465,022 held (−3%) $12.43 $23K +5.1% —
Aug 24SEC John M LeonardCEO, President Sell Plan 19,8901,149,849 held (−2%) $12.60 $251K +3.7% —
Aug 24SEC John M LeonardCEO, President Sell Plan 2,7851,147,064 held (−0%) $13.00 $36K +0.5% —
Jul 24SEC Edward J Dulac IIICFO Sell 8,111148,175 held (−5%) $11.25 $91K +16.2% —
Jul 6SEC Edward J Dulac IIICFO Sell Plan 4,677156,286 held (−3%) $18.00 $84K -27.4% —
Jul 6SEC Michael P DubeVp, Chief Accounting Officer Sell 2,64166,886 held (−4%) $16.78 $44K -22.1% —
Mar 3SEC James BastaGeneral Counsel Sell 1,211156,794 held (−1%) $13.78 $17K -5.2% —
Mar 3SEC Eliana ClarkEvp, Chief Technical Officer Sell 60793,864 held (−1%) $13.78 $8K -5.2% —
Jan 7SEC Fred E CohenDirector Buy 150,000207,453 held (+261%) $9.35 $1.4M +39.8% —
Jan 7SEC John M LeonardCEO, President Sell 34,1461,013,339 held (−3%) $9.21 $314K +41.9% —
Jan 7SEC David LebwohlEvp, Chief Medical Officer Sell 11,903121,249 held (−9%) $9.21 $110K +41.9% —
Jan 7SEC James BastaGeneral Counsel Sell 10,397101,528 held (−9%) $9.21 $96K +41.9% —
Jan 7SEC Eliana ClarkEvp, Chief Technical Officer Sell 9,51587,118 held (−10%) $9.21 $88K +41.9% —
Jan 7SEC Birgit C SchultesEvp, Chief Scientific Officer Sell 8,50898,533 held (−8%) $9.21 $78K +41.9% —
Jan 7SEC Edward J Dulac IIICFO Sell 6,37999,683 held (−6%) $9.21 $59K +41.9% —
Jan 7SEC Michael P DubeVp, Chief Accounting Officer Sell 2,98952,277 held (−5%) $9.21 $28K +41.9% —
Dec 12SEC John M LeonardCEO, President Sell Plan 49,9591,077,115 held (−4%) $9.49 $474K +37.7% —
Dec 12SEC John M LeonardCEO, President Sell Plan 32,8321,044,283 held (−3%) $9.47 $311K +38.0% —
Dec 12SEC John M LeonardCEO, President Sell Plan 5,3551,038,928 held (−1%) $9.59 $51K +36.3% —
Oct 3SEC Michael P DubeVp, Chief Accounting Officer Sell 1,87155,266 held (−3%) $17.38 $33K -24.8% —
Oct 3SEC Birgit C SchultesEvp, Chief Scientific Officer Sell 31105,184 held (−0%) $17.38 $539 -24.8% —

Insiders at Intellia Therapeutics, Inc.

InsiderBoughtSoldLast filingScore
Fred E CohenDirector $1.4M — Jan 7, 2026 —
John M LeonardCEO, President — $1.4M Aug 24, 2026 —
Edward J Dulac IIICFO — $234K Jul 24, 2026 —
Michael P DubeVp, Chief Accounting Officer — $128K Oct 6, 2026 —
James BastaGeneral Counsel — $112K Mar 3, 2026 —
David LebwohlEvp, Chief Medical Officer — $110K Jan 7, 2026 —
Eliana ClarkEvp, Chief Technical Officer — $96K Mar 3, 2026 —
Birgit C SchultesEvp, Chief Scientific Officer — $79K Jan 7, 2026 —

NTLA stock: common questions

Are Intellia Therapeutics, Inc. insiders buying NTLA stock?

In the past 12 months, 1 insiders reported open-market purchases of NTLA worth $1.4M. The latest was Director Fred E Cohen bought $1.4M of NTLA at $9.35 — first open-market purchase in our records; raises the stake by 261%.

Are Intellia Therapeutics, Inc. insiders selling NTLA stock?

7 insiders reported sales worth $2.2M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is NTLA's 52-week range?

Over the past year NTLA has traded between $8.04 and $27.98. It last closed at $13.07 on Oct 9, 2026.